var title_f40_4_41024="Closure rectovaginal fistula3";
var content_f40_4_41024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a small rectovaginal fistula through a transvaginal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The puborectalis fibers are reapproximated in the midline to give a third layer of closure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41024=[""].join("\n");
var outline_f40_4_41024=null;
var title_f40_4_41025="Bacillary angiomatosis in HIV";
var content_f40_4_41025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bacillary angiomatous lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The small papule with a smooth, reddish, glistening and obviously vascular appearance is more typical than the larger lesion, which is hyperkeratotic, drier, and polypoid. Courtesy of Leonard N Slater, MD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41025=[""].join("\n");
var outline_f40_4_41025=null;
var title_f40_4_41026="Patient information: Nose fracture (The Basics)";
var content_f40_4_41026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82971\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/49/31507\">",
"         Skull bones",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/21/16735\">",
"          How to stop a nosebleed",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/50/1826\">",
"         Patient information: Nosebleeds (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/24/34178\">",
"         Patient information: Skull and facial fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/10/19617\">",
"         Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nose fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nose-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2362722\">",
"      <span class=\"h1\">",
"       What is a nose fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A &ldquo;fracture&rdquo; is another word for a broken bone. A nose fracture is when a person breaks a bone in the nose (",
"      <a class=\"graphic graphic_figure graphicRef62443 \" href=\"mobipreview.htm?30/49/31507\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      There are different kinds of nose fractures, depending on how the bone breaks. Some fractures are more serious than others. If the bone is only cracked, the fracture is usually not as serious. But if a bone is pushed out of position, the fracture is more serious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362737\">",
"      <span class=\"h1\">",
"       What are the symptoms of a nose fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a nose fracture include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Trouble breathing through the nose",
"       </li>",
"       <li>",
"        Bleeding from the nose or clear fluid draining from the nose",
"       </li>",
"       <li>",
"        Being unable to smell",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A nose fracture can also make the nose look crooked or bent.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362752\">",
"      <span class=\"h1\">",
"       What if my nose is bleeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your nose is bleeding, you can follow these steps to help stop the bleeding:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bend forward a little at the waist when you sit or stand. Do NOT lie down or tilt your head back.",
"       </li>",
"       <li>",
"        Firmly pinch together the soft area towards the bottom of your nose, below the bone, using your thumb and finger (",
"        <a class=\"graphic graphic_picture graphicRef62213 \" href=\"mobipreview.htm?16/21/16735\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Hold a cold gel pack, bag of ice, or bag of frozen vegetables on your nose for a few minutes at a time. Try to put a thin towel between the ice (or other cold object) and your skin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the bleeding continues, you can gently put some gauze or a cotton ball in your nose.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362767\">",
"      <span class=\"h1\">",
"       Is there a test for a nose fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people need tests. Your doctor or nurse will ask about your injury and symptoms, and do an exam. Depending on your injury and symptoms, he or she might do an X-ray or CT scan. A CT scan is an imaging test that creates pictures of the inside of the body.",
"     </p>",
"     <p>",
"      <strong>",
"       How are nose fractures treated?",
"      </strong>",
"      &ndash; For the first 1 to 2 days after your injury, you can help reduce swelling by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keeping your head above the level of your heart (and not lying down flat)",
"       </li>",
"       <li>",
"        Putting ice on your nose &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. You should put a thin towel between the ice (or other cold object) and your skin. You should use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have a lot of pain or a severe fracture, your doctor will prescribe a strong pain medicine. If you have a mild fracture, he or she will recommend that you take an over-the-counter medicine for your pain. Over-the-counter medicines include",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      Other treatment depends on how mild or severe your nose fracture is. If your nose bones are in the correct position and you can breathe through both nostrils, your nose fracture is mild. You probably won&rsquo;t need other treatment. But your doctor might want to check your nose again after the swelling has gotten better.",
"     </p>",
"     <p>",
"      If you have a collection of blood in your nose, the doctor will drain the blood. Then he or she will put &ldquo;packing material&rdquo; in your nose for a few days to stop the bleeding.",
"     </p>",
"     <p>",
"      If your injury pushed your nose bones out of position, the bones will need to be put back in the correct position. Doctors can sometimes put the nose bones back in the correct position by doing a procedure.",
"     </p>",
"     <p>",
"      But if this procedure doesn&rsquo;t work, or you have a severe nose fracture, you will need surgery. Nose surgery is usually done by a specialist called an ear, nose, and throat doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362782\">",
"      <span class=\"h1\">",
"       How long do nose fractures take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most nose fractures take weeks to heal. The healing time depends on how mild or severe the fracture is.",
"     </p>",
"     <p>",
"      Healing time also depends on the person. Healthy children usually heal much more quickly than older adults or adults with other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362797\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your nose fracture is healing. For example, she or she might recommend that you avoid doing certain activities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362812\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call him or her if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your pain or swelling gets worse.",
"       </li>",
"       <li>",
"        Your nose is bleeding a lot, or clear fluid is leaking from your nose.",
"       </li>",
"       <li>",
"        You are having trouble breathing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2362827\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/24/34178?source=see_link\">",
"       Patient information: Skull and facial fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/50/1826?source=see_link\">",
"       Patient information: Nosebleeds (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/10/19617?source=see_link\">",
"       Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/4/41026?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82971 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41026=[""].join("\n");
var outline_f40_4_41026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362722\">",
"      What is a nose fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362737\">",
"      What are the symptoms of a nose fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362752\">",
"      What if my nose is bleeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362767\">",
"      Is there a test for a nose fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362782\">",
"      How long do nose fractures take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362797\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362812\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2362827\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/49/31507\">",
"      Skull bones",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/21/16735\">",
"       How to stop a nosebleed",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/50/1826?source=related_link\">",
"      Patient information: Nosebleeds (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/10/19617?source=related_link\">",
"      Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_4_41027="ACP algorithm management low or intermediate risk patients";
var content_f40_4_41027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73341%7ECARD%2F60714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73341%7ECARD%2F60714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    American College of Physicians algorithm for the risk assessment and managment of patients at low or intermediate risk for perioperative cardiac events (myocardial infarction and death)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 556px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Boxed phrases indicate recommended actions.",
"    <br>",
"     The green bolded words beside the boxes indicate the level of evidence supporting the recommendation. If no green bolded word is present, no evidence exists for or against use.",
"     <div class=\"footnotes\">",
"      DTI: dipyridamole thallium imaging; DSE: dobutamine stress echocardiography.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from Palda, et al. Ann Intern Med 1997; 127:309. Copyright &copy; 1997 American College of Physicians.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    American College of Physicians algorithm for the management of patients at high risk for perioperative cardiac events (myocardial infarction and death)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 450px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Boxed phrases indicate recommended actions.",
"    <br>",
"     The green bolded words beside the boxes indicate the level of evidence supporting the recommendation. If no green bolded word is present, no evidence exists for or against use.",
"     <div class=\"footnotes\">",
"      AHA: American Heart Association.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from Palda, et al. Ann Intern Med 1997; 127:309. Copyright &copy; 1997 American College of Physicians.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41027=[""].join("\n");
var outline_f40_4_41027=null;
var title_f40_4_41028="Transverse acetabular fracture";
var content_f40_4_41028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse acetabular fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The anteroposterior pelvis view demonstrates disruption of four of the six radiograph landmarks of the acetabulum with the ilioischial line maintaining its normal relationship with the radiographic U (arrow), indicating that this is a transverse fracture below the level of the roof. Note the subluxation of the femoral head away from the intact portion of the acetabular roof.",
"    <br/>",
"    (B) The obturator oblique view shows a break in the iliopectineal line (arrow) and subluxation of the femoral head with the displacement of the ischiopubic segment and verifies that the ischial ramus is not broken.",
"    <br/>",
"    (C) The iliac oblique shows where the transverse fracture exits the greater sciatic notch (arrow) and again confirms the subluxation of the femoral head.",
"    <br/>",
"    (D) This computed tomography section shows the orientation typical of a transverse fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41028=[""].join("\n");
var outline_f40_4_41028=null;
var title_f40_4_41029="Guide to health information resources for patients";
var content_f40_4_41029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Guide to health information resources for patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41029/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/4/41029/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often seek to learn about health and disease on their own. A Harris Poll in 2010 found that 79 percent of American adults use the internet, and 62 percent of them looked online for health or medical information in the past month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/1\">",
"     1",
"    </a>",
"    ]. Many use cell phones for this purpose, especially those who are younger (in the 18 to 29 year old age group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients are increasingly connecting with each through social media such as websites like &ldquo;Patients Like Me&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/3\">",
"     3",
"    </a>",
"    ] that might offer informal support and education but may not be appropriate to the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A vast amount of information is available in print and electronic media. However, this information is of variable quality, and it is often difficult for laymen to decide whether or not a particular source of information is credible.",
"   </p>",
"   <p>",
"    This topic presents a road map to some of the most respected sources of information for patients, especially those available on the web. We have not attempted to describe all sources of health information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE CLINICIAN'S ROLE IN PATIENT INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A motivated patient can discover more information on any specific topic of interest than is feasible for his or her clinician to look up. This is a relatively recent phenomenon, made possible by the availability of electronic information and encouraged by the movement toward sharing decision-making between patients and clinicians.",
"   </p>",
"   <p>",
"    Clinicians should be prepared to recommend credible websites to interested patients. They should recognize the added value in having conversations with well-informed patients and not compete with them for mastery of facts or become defensive. In one study, 67 percent of patients in a community-based primary care practice agreed that clinicians should recommend specific websites where they could find health information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinicians should encourage patients to bring them information, while counseling them on the quality of sources, weighing validity, and putting facts in context. This may require setting aside time to review the information.",
"   </p>",
"   <p>",
"    Clinicians' special contributions to discussions with well-informed patients are based on competencies these patients are unlikely to have:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Understanding the biology of disease",
"     </li>",
"     <li>",
"      Familiarity with how a disease presents and its signs and symptoms",
"     </li>",
"     <li>",
"      Understanding the process by which good science is developed and disseminated by well-trained scholars in centers of excellence, and publication in peer reviewed journals sponsored by respected professional societies.",
"     </li>",
"     <li>",
"      Skill in critical appraisal of clinical research reports, including a well-developed appreciation of the hierarchy of strength of research designs (from large randomized controlled trials down to case reports) and generalizability from study patients to the person of interest.",
"     </li>",
"     <li>",
"      Appreciation of the distinction between arguments for what ought to happen, based on knowledge of the mechanisms of disease, and what has been shown to actually happen in well-designed and well-conducted clinical research on patients",
"     </li>",
"     <li>",
"      The difference between isolated observations (eg, a case report or a single randomized trial) and coherent patterns of all relevant evidence",
"     </li>",
"     <li>",
"      Skepticism about information from biased sources, such as authors with financial conflicts of interest, intellectual zeal, or a wish for personal aggrandizement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most clinicians now use the internet. In a 2009 survey by the American Medical Association, 86 percent of clinicians used the internet to find health information and 29 percent of those accessed the internet from their office [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/6\">",
"     6",
"    </a>",
"    ]. In a study of cancer-related internet information, patients of clinicians who took internet information seriously had greater satisfaction with care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/7\">",
"     7",
"    </a>",
"    ]. There is a US national effort to bring information technology to medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE MEDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient information is available in magazines, books, newsletters, radio, television, websites, hotlines, and many other media. Quality is judged by the same criteria regardless of how information is accessed (",
"    <a class=\"graphic graphic_table graphicRef77186 \" href=\"mobipreview.htm?21/5/21596\">",
"     table 1",
"    </a>",
"    ). Which medium is best depends entirely on patients' preferences. We will focus on websites, the most convenient medium for finding the most current information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WEBSITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Wide Web contains an extraordinary array of information on medical matters. The move to \"open access\" to medical journals, through PubMed Central [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/9\">",
"     9",
"    </a>",
"    ] and the journals themselves, is making an increasing proportion of original research articles available to the general public.",
"   </p>",
"   <p>",
"    Web information is available for both common and rare conditions. However, the quality of what now exists on the web is extraordinarily variable. For example, a systematic review of the quality of patient information on the internet regarding inflammatory bowel disease found 50 websites, although quality was variable and few sites provided high-quality information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biased information and advocacy in the form of advertisements and other promotions exist alongside the most respected sources of information. Even sound sources of information tend to be lax in providing credentials and procedures, relative to what is required for most peer-reviewed print publications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FINDING TRUSTWORTHY INFORMATION ON THE WEB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can use different approaches to finding the information they need (",
"    <a class=\"graphic graphic_figure graphicRef71366 \" href=\"mobipreview.htm?0/26/430\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Look at sites recommended by a trusted advisor, such as the Medical Library Association, or the National Institutes of Health (see below).",
"     </li>",
"     <li>",
"      Examine specific sites that are trustworthy, such as UpToDate.",
"     </li>",
"     <li>",
"      Health on the Net Foundation is a nonprofit, international group that awards &ldquo;The HON Code of conduct for medical and health Web sites (HONcode)&rdquo; as a seal of certification, intended to ensure the quality of the information on the sites that earn it. Sites such as Mayo Clinic (",
"      <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"       file://www.mayoclinic.com/",
"      </a>",
"      ) display the seal logo at the bottom of their home page.",
"     </li>",
"     <li>",
"      Ask a specific question using a general search engine, such as Google, find multiple sites, and judge the quality for themselves guided by criteria discussed below (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Judging the quality of website information'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some websites, especially those sponsored by governments, medical schools, and major professional organizations, are worth going to first. Many offer information in several media, such as electronic databases, newsletters (both electronic and in print), and books.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     UpToDate",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Basics patient education pieces are written in plain language, and answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"     </li>",
"     <li>",
"      Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the patient information materials in UpToDate are based upon UpToDate contents for clinicians, and similar to the clinician topics, the patient topics are regularly reviewed and updated. To find relevant patient information topics within UpToDate, search for the keyword of interest and &ldquo;prioritize&rdquo; by patient information. Patient topics, if available, will appear at the top of the search results. It is also possible to add the words \"patient information\" or &ldquo;patient info&rdquo; to any search term to get a list of available patient information topics.",
"   </p>",
"   <p>",
"    The Basics patient information library is available only to authenticated users of UpToDate. Clinicians who have UpToDate access either by personal or institutional subscription are encouraged to locate and print materials from the site for their patients. &nbsp;",
"   </p>",
"   <p>",
"    The Beyond the Basics patient information library is freely available on the web. That material can be accessed through the main search function, and through a separate patient information website (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients who want access to the complete UpToDate content, including more than 8000 clinician-oriented topics, can pay a small fee for time-limited access to the full program. This can be obtained through &ldquo;subscription options for patients&rdquo; on the website www.uptodate.com.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sites recommended by the Medical Library Association",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Consumer and Patient Health Information Section (CAPHIS) of the Medical Library Association has a link that lists \"General Health Web Sites You Can Trust.\" A list of the top 100 can be found at",
"    <a class=\"external\" href=\"file://caphis.mlanet.org/consumer\">",
"     file://caphis.mlanet.org/consumer",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Federal government",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States federal government offers many useful websites as part of a larger effort to increase public access to NIH-funded research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medline Plus (",
"      <a class=\"external\" href=\"file://medlineplus.nlm.nih.gov/medlineplus\">",
"       medlineplus.nlm.nih.gov/medlineplus",
"      </a>",
"      ), developed by the National Library of Medicine, directs lay people to resources with medical information. This site includes drug information, a medical encyclopedia, a medical dictionary, news, and directions for finding doctors, as well as links to other sites.",
"     </li>",
"     <li>",
"      HealthFinder (",
"      <a class=\"external\" href=\"file://www.healthfinder.gov/\">",
"       www.healthfinder.gov",
"      </a>",
"      ) is a free service developed by the Department of Health and Human Services. It links users to reliable consumer health information megasites for health professionals.",
"     </li>",
"     <li>",
"      Health Hotlines (",
"      <a class=\"external\" href=\"file://healthhotlines.nlm.nih.gov/\">",
"       healthhotlines.nlm.nih.gov",
"      </a>",
"      ) is an online database of health-related organizations operating toll-free telephone services, in both English and Spanish. It is maintained by the National Library of Medicine.",
"     </li>",
"     <li>",
"      The National Cancer Institute (NCI) (",
"      <a class=\"external\" href=\"file://www.cancer.gov/\">",
"       www.cancer.gov",
"      </a>",
"      ) includes information for the lay public on screening, diagnosis, and treatment of each type of cancer. The NCI also sponsors PDQ, a comprehensive cancer database.",
"     </li>",
"     <li>",
"      The Centers for Disease Control (CDC) (",
"      <a class=\"external\" href=\"file://www.cdc.gov/\">",
"       www.cdc.gov",
"      </a>",
"      ) provide information on disease prevention both in everyday life and for international travel, including recommended immunizations and prophylaxis for malaria and other diseases for each country.",
"     </li>",
"     <li>",
"      The Food and Drug Administration (FDA) (",
"      <a class=\"external\" href=\"file://www.fda.gov/\">",
"       www.fda.gov",
"      </a>",
"      ) posts information on drugs and devices, including recalls.",
"     </li>",
"     <li>",
"      The National Institutes of Health (NIH) (",
"      <a class=\"external\" href=\"file://www.nih.gov/\">",
"       www.nih.gov",
"      </a>",
"      ) offer a comprehensive set of health information for patients, such as clinical trials (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct/gui/c/b\">",
"       clinicaltrials.gov/ct/gui/c/b",
"      </a>",
"      ) and health hotlines, in many instances through links to the websites of other federal health agencies.",
"     </li>",
"     <li>",
"      The National Library of Medicine (NLM) (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/\">",
"       www.nlm.nih.gov",
"      </a>",
"      ) offers a Genetics Home Reference, a toxicology database, and other information including links similar to the NIH site.",
"     </li>",
"     <li>",
"      Clinical practice guidelines are summarized at the National Guideline Clearinghouse (",
"      <a class=\"external\" href=\"file://www.guidelines.gov/\">",
"       www.guidelines.gov",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other countries also have information for patients and may interpret the evidence differently than the United States, because of their cultural or financial priorities. For example, The National Institute for Health and Clinical Excellence (NICE) is an independent organization based in the National Health Service of England and Wales (",
"    <a class=\"external\" href=\"file://www.nice.org.uk/\">",
"     www.nice.org.uk",
"    </a>",
"    ). Family physicians in the United Kingdom have established a website for patients (",
"    <a class=\"external\" href=\"file://www.patient.co.uk\">",
"     www.patient.co.uk",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medical schools and centers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medical schools offer patient information, both web-based and more traditional newsletters and health books.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Harvard Medical School offers a website (",
"      <a class=\"external\" href=\"file://www.health.harvard.edu/\">",
"       www.health.harvard.edu",
"      </a>",
"      ) that describes how patients can obtain several newsletters tailored to special interests such as men's, women's, and mental health. A website also contains consumer information and basic information on many diseases and a focus on preventive health (",
"      <a class=\"external\" href=\"file://www.health.harvard.edu/\">",
"       www.health.harvard.edu",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Washington University sponsors a website,",
"      <a class=\"external\" href=\"file://www.yourdiseaserisk.wustl.edu/\">",
"       Your Disease Risk",
"      </a>",
"      , where users can calculate their risk of several chronic diseases (cancer, diabetes, heart disease, osteoporosis, and stroke).",
"     </li>",
"     <li>",
"      The Mayo Clinic (",
"      <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"       www.mayoclinic.com",
"      </a>",
"      ) has an extensive web site with summaries of medical conditions written for the lay public. Patients can use a simple search mechanism or look under various health centers. The site also offers a broad array of books, newsletters, and booklets for patients.",
"     </li>",
"     <li>",
"      The University of California, Berkeley (",
"      <a class=\"external\" href=\"file://www.berkeleywellnessalerts.com/\">",
"       www.berkeleywellnessalerts.com/",
"      </a>",
"      ) offers The Newsletter of Nutrition, Fitness, and Self Care in electronic form, as well as related books.",
"     </li>",
"     <li>",
"      Tufts University (",
"      <a class=\"external\" href=\"file://www.healthletter.tufts.edu/\">",
"       www.healthletter.tufts.edu",
"      </a>",
"      ) offers Tufts Health and Nutrition Letter in electronic form.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Professional organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some professional organizations, such as the",
"    <a class=\"external\" href=\"file://www.heart.org/HEARTORG/\">",
"     American Heart Association",
"    </a>",
"    , also offer carefully prepared, balanced patient information, though one should have a higher index of suspicion that the sites serve the interests of the sponsoring organization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patient advocacy organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient advocacy organization exists for just about every major disease. These organizations provide information and education, organize support groups (in person and virtual), and offer opportunities to donate to research and service programs. The best way to find them is through the web, either through Google (",
"    <a class=\"external\" href=\"file://www.google.com/\">",
"     www.google.com",
"    </a>",
"    ) or HealthFinder (",
"    <a class=\"external\" href=\"file://www.healthfinder.gov/\">",
"     www.healthfinder.gov",
"    </a>",
"    ). The health hotline (",
"    <a class=\"external\" href=\"file://healthhotlines.nlm.nih.gov/\">",
"     healthhotlines.nlm.nih.gov",
"    </a>",
"    ) gives phone numbers and addresses of many of these groups.",
"   </p>",
"   <p>",
"    The American Cancer Society (",
"    <a class=\"external\" href=\"file://www.cancer.org/\">",
"     www.cancer.org",
"    </a>",
"    ), one of the largest, provides patient information on cancer prevention and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Commercial websites",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of commercial sites, such as WebMD, offer information for patients on a broad range of conditions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Searching by a specific question",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient looks for web information on a specific topic by using a search engine such as Google, many different sites, of varying quality, will come up. Credible information is available on the web not only for common problems but for relatively obscure medical problems. In our experience, at this point in time, the sites suggested first tend to be from credible sources. Nevertheless, patients should look for the sponsor of any site they consult and apply criteria for judging the site (",
"    <a class=\"graphic graphic_table graphicRef77186 \" href=\"mobipreview.htm?21/5/21596\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Research citations can be found through PubMed, Google Scholar, Scopus, and Web of science; they are for scholars but may be useful for some patients. They retrieve different citations for similar searches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41029/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     JUDGING THE QUALITY OF WEBSITE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can judge the quality of a website for themselves, guided by criteria developed by the Medical Library Association and available on the Internet (",
"    <a class=\"external\" href=\"file://www.mlanet.org/resources/userguide.html\">",
"     www.mlanet.org/resources/userguide.html#3",
"    </a>",
"    ). This tool will guide the user through a series of questions to evaluate a health information site. Another guide is A User's Guide to Finding and Evaluating Health Information on the Web (",
"    <a class=\"external\" href=\"file://www.healthfinder.gov/\">",
"     www.healthfinder.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The recommended information is usually available on reputable sites, although users may have to work to find it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BOOKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many families want to have a book on general health information in their homes. Among the reputable books are some produced and edited by professional organizations or medical schools:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Medical Association Family Medicine Guide, 4th Ed. Indianapolis, IN, Wiley, 2004",
"     </li>",
"     <li>",
"      Harvard Medical School and Komaroff AL. Harvard Medical School Family Health Guide, 1st Edition. New York; Simon and Shuster, 2005.",
"     </li>",
"     <li>",
"      Mayo Clinic. Mayo Clinic Family Health Book, 4th Ed. &nbsp;New York Time Home Entertainment Inc. 2009",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these books have an accompanying website, which may provide more current information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER MEDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;More traditional media remain the main way in which patients are exposed to health information outside of doctors' offices, especially for the elderly who are less likely to use the internet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Magazines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some magazines publish particularly responsible and effective articles about medical issues. Among them are Consumer Reports and Atlantic Monthly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medical news",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major newspapers such as The New York Times and The Washington Post have excellent medical writers, many of whom have medical and other scientific backgrounds and an extraordinary ability to capture the essence of medical issues without distortion or oversimplification.",
"   </p>",
"   <p>",
"    Clinicians who wish to keep up with medical issues in the news, as it is released (so as not to be surprised by patients' questions about news articles) can find coverage of the top stories of the day on the web. Examples of such sites are www.medicalnewstoday.com and www.webmd.com. The New England Journal of Medicine offers subscribers a daily, computer-based update of medical news called Physician's First Watch (",
"    <a class=\"external\" href=\"file://www.jwatch.org/\">",
"     www.jwatch.org",
"    </a>",
"    ). Media coverage of recently publicized research can be found using a search engine such as Google.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662149435\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the wealth of medical information freely available on the Internet and the extensive use of this medical content by the general public, clinicians should be prepared to recommend credible websites to interested patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The clinician's role in patient information'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Consumer and Patient Health Information Section (CAPHIS) of the Medical Library Association has a link that lists \"General Health Web Sites You Can Trust.\" A list of the top 100 can be found at",
"      <a class=\"external\" href=\"file://caphis.mlanet.org/consumer\">",
"       file://caphis.mlanet.org/consumer",
"      </a>",
"      . Multiple sites from government agencies in the US and the United Kingdom are listed, as well as sites from universities and professional organizations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Finding trustworthy information on the web'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients can judge the quality of a website for themselves, guided by criteria developed by the Medical Library Association and available on the Internet (",
"      <a class=\"external\" href=\"file://www.mlanet.org/resources/userguide.html\">",
"       www.mlanet.org/resources/userguide.html#3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Judging the quality of website information'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.harrisinteractive.com/vault/HI-Harris-Poll-Cyberchondriacs-2010-08-04.pdf (Accessed on December 07, 2010).",
"    </li>",
"    <li>",
"     file://www.pewinternet.org/Reports/2007/Information-Searches-That-Solve-Problems.aspx (Accessed on December 07, 2010).",
"    </li>",
"    <li>",
"     www.patientslikeme.com (Accessed on December 13, 2010).",
"    </li>",
"    <li>",
"     www.pewinternet.org/Reports/2009/8-The-Social-Life-of-Health-Information.aspx (Accessed on December 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41029/abstract/5\">",
"      Diaz JA, Sciamanna CN, Evangelou E, et al. Brief report: What types of Internet guidance do patients want from their physicians? J Gen Intern Med 2005; 20:683.",
"     </a>",
"    </li>",
"    <li>",
"     file://ama-assn.org/amednews/2010/01/04/bisc0104.htm (Accessed on December 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41029/abstract/7\">",
"      Bylund CL, Gueguen JA, D'Agostino TA, et al. Doctor-patient communication about cancer-related internet information. J Psychosoc Oncol 2010; 28:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41029/abstract/8\">",
"      Blumenthal D, Glaser JP. Information technology comes to medicine. N Engl J Med 2007; 356:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41029/abstract/9\">",
"      Steinbrook R. Public access to NIH-funded research. N Engl J Med 2005; 352:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41029/abstract/10\">",
"      Langille M, Bernard A, Rodgers C, et al. Systematic review of the quality of patient information on the internet regarding inflammatory bowel disease treatments. Clin Gastroenterol Hepatol 2010; 8:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41029/abstract/11\">",
"      Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA 2009; 302:1092.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2771 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41029=[""].join("\n");
var outline_f40_4_41029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H662149435\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE CLINICIAN'S ROLE IN PATIENT INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE MEDIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WEBSITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FINDING TRUSTWORTHY INFORMATION ON THE WEB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UpToDate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sites recommended by the Medical Library Association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Federal government",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medical schools and centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Professional organizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patient advocacy organizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Commercial websites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Searching by a specific question",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      JUDGING THE QUALITY OF WEBSITE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BOOKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER MEDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Magazines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medical news",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662149435\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2771|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/26/430\" title=\"figure 1\">",
"      Patient info search strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/5/21596\" title=\"table 1\">",
"      Judging quality websites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_4_41030="Management of psoriasis in pregnant women";
var content_f40_4_41030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of psoriasis in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Miriam Keltz Pomeranz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Bruce E Strober, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41030/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/4/41030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is a chronic skin disorder characterized by well-demarcated erythematous papules and plaques with a silver scale, although atypical or nonclassic forms also exist. It commonly occurs on the extensor surface of the elbows or knees, or the scalp. Psoriasis commonly occurs in women of reproductive age as three-quarters of patients develop the disease before reaching age 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of psoriasis in pregnant women will be reviewed here. The general treatment of psoriasis and pustular psoriasis of pregnancy, a severe pustular form of psoriasis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29657?source=see_link\">",
"     \"Dermatoses of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREGNANCY COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have investigated the impact of psoriasis on pregnancy outcomes, and the available studies have yielded varying results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective cohort study of 3131 pregnancies in women with inflammatory skin diseases and 2592 pregnancies in women without inflammatory skin diseases found similar rates of pregnancy and spontaneous abortion in both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study of 1463 mothers with psoriasis and 11,704 mothers without psoriasis, women with severe psoriasis (defined as those who had received photochemotherapy or systemic therapy within two years before delivery) had a higher risk for the delivery of low birth weight infants compared with mothers without psoriasis (adjusted OR = 1.40, 95% CI 1.04-1.89) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/3\">",
"       3",
"      </a>",
"      ]. Receiving systemic therapy during pregnancy did not appear to contribute to the increased risk of low birth weight; rates of low birth infants were similar among mothers who received systemic medications during pregnancy and those who did not.",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 68 deliveries in 35 women with moderate to severe psoriasis and 237 deliveries in 236 women without psoriasis, psoriasis was identified as an independent risk factor for spontaneous abortions, induced abortions, premature rupture of membranes, and infant macrosomia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are necessary to clarify the impact of psoriasis on pregnancy outcomes.",
"   </p>",
"   <p>",
"    Choosing drug therapies that pose the least risk to the fetus is the major issue in managing the pregnancies of affected women. Women should try to plan pregnancy when they are in remission, and ideally when they are off medication or are taking the minimum effective dose of medications that have the best fetal safety profiles. Psoriasis improves during pregnancy in 40 to 60 percent of women, worsens in 10 to 20 percent, and remains stable in the remainder; however, the disease flares in 50 percent of women postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children of women with psoriasis have an increased risk for the development of the disorder. The risk of an affected offspring is 28 percent if one parent is affected, and 65 percent if both parents are affected (multifactorial inheritance pattern) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of psoriasis can be divided into three broad categories: topical therapy, phototherapy, and systemic therapy, which has two subcategories: classic medications and the newer biologic agents. Choice of therapy is based upon the severity of the disease and its impact on the patient's overall sense of well-being, relevant comorbidities, patient preference (including cost and convenience), efficacy, and evaluation of individual patient response. A stepwise approach to management is practical and effective, although the initial steps of the therapeutic ladder are sometimes by-passed in patients with more",
"    <span class=\"nowrap\">",
"     extensive/severe",
"    </span>",
"    disease.",
"   </p>",
"   <p>",
"    The treatment paradigm is the same for both pregnant and nonpregnant patients, except some medications are avoided in pregnancy and the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio may be calculated differently because fetal risk must also be taken into account [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/9\">",
"     9",
"    </a>",
"    ]. We agree with a recommendation from the Medical Board of the National Psoriasis Foundation that topical treatment with a low or medium potency topical corticosteroid is the first-line therapeutic intervention for pregnant women with limited psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/10\">",
"     10",
"    </a>",
"    ]. UVB phototherapy (particularly narrowband UVB) is the preferred treatment for women with more severe symptoms.",
"   </p>",
"   <p>",
"    Treatment of nonpregnant individuals is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14842?source=see_link\">",
"     \"Treatment selection for moderate to severe plaque psoriasis in special populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TOPICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy is appropriate for localized disease. The simplest topical therapies are emollients, which may control bothersome scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For mild psoriasis, intermittent topical corticosteroids may control disease with no or minimal maternal or fetal risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Most topical corticosteroids are classified by the Food and Drug Administration (FDA) as pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Topical corticosteroids of high potency, in large amounts, with occlusive dressings, for prolonged periods of time appear to have caused fetal abnormalities in animals, although none have been documented in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/13\">",
"     13",
"    </a>",
"    ]. Used in this way, they may be associated with low birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corticosteroids are excreted into the breast milk, but their use during lactation is deemed compatible with breastfeeding by the American Academy of Pediatrics (AAP) if justified by the potential benefit to the health of the mother [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/15\">",
"     15",
"    </a>",
"    ]. No adverse effects have been noted in breast fed infants, but it is prudent to avoid applying corticosteroids to the nipples prior to nursing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/14\">",
"     14",
"    </a>",
"    ]. These drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Use during pregnancy or lactation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For pregnant women who will be treated with topical corticosteroids for psoriasis, the use of low or medium potency topical corticosteroids is preferred (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/10\">",
"     10",
"    </a>",
"    ]. We typically reserve the use of high potency topical corticosteroids for patients who fail treatment with lower potency topical corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcipotriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/54/5988?source=see_link\">",
"     Calcipotriol (calcipotriene)",
"    </a>",
"    , a vitamin D3 derivative, is FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ), but carries a manufacturer's warning to avoid its use during pregnancy. Studies in rats and rabbits have not reported an increased risk of congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/16\">",
"     16",
"    </a>",
"    ]. Hypercalcemia has been reported with excessive topical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/17\">",
"     17",
"    </a>",
"    ], and excessive vitamin D intake can lead to skeletal abnormalities in offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/16\">",
"     16",
"    </a>",
"    ]; however, this is unlikely with limited topical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/12,14,18\">",
"     12,14,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no information on use in breastfeeding women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/15\">",
"     15",
"    </a>",
"    ]. Given that calcipotriene is a derivative of vitamin D, its use is probably compatible with nursing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coal tar",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44724?source=see_link\">",
"     Coal tar",
"    </a>",
"    is FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). A case series including 23 women who used coal tar products during pregnancy did not detect an increase in congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/19\">",
"     19",
"    </a>",
"    ]. Topical coal tar can be considered for use in the second and third trimesters, although topical application can result in systemic absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no information on use in breastfeeding women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/15\">",
"     15",
"    </a>",
"    ]. The manufacturer suggests avoiding use during lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) are classified as FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). They are a relatively new category of topical drugs that are not particularly effective in psoriasis; however, they are occasionally used when topical corticosteroids must be avoided. Based on experimental animal studies and human case reports, these drugs do not appear to increase the risk of congenital anomalies. However, neonatal renal effects have been reported in exposed offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/16\">",
"     16",
"    </a>",
"    ]. These drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tazarotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     Tazarotene",
"    </a>",
"    is a retinoid approved for the topical treatment of psoriasis. Less than 1 percent of the dose is absorbed on psoriatic skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     Tazarotene",
"    </a>",
"    is FDA pregnancy category X (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) and should",
"    <strong>",
"     NOT",
"    </strong>",
"    be given to pregnant or breastfeeding women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. Tazarotene is avoided during pregnancy and lactation based on good data that another retinoid (oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ) is associated with a significant increase in major congenital malformations. First trimester oral isotretinoin exposure is strongly associated with embryopathy, including craniofacial, cardiac, thymic, and central nervous system malformations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link&amp;anchor=H8#H8\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Teratogenicity and the iPLEDGE program'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHOTOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy is recommended for patients with moderate disease who fail or cannot use topical therapies. Although it is externally applied, it is considered a systemic treatment since it can be used to treat the entire cutaneous surface area.",
"   </p>",
"   <p>",
"    Narrow band ultraviolet B phototherapy (NBUVB) at wavelength 311 appears to be a safe and often effective treatment of psoriasis in pregnant woman [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The major disadvantage of this approach is the need to travel to a clinic three days per week for treatment. Localized disease can be treated with a 308 nm laser [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of systemic psoralen and ultraviolet A phototherapy (PUVA) is more controversial during pregnancy. Some experts suggest it can be used if the psoralen is applied topically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/12\">",
"     12",
"    </a>",
"    ]. One expert places it in the therapeutic algorithm before oral systemic treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The topical therapies discussed above are generally also required as adjuvant therapy and for symptomatic relief.",
"   </p>",
"   <p>",
"    There is minimal information on use of psoralen or phototherapy in breastfeeding women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/15\">",
"     15",
"    </a>",
"    ]. One expert suggested that nursing women avoid use of psoralen because it might photosensitize the baby.",
"   </p>",
"   <p>",
"    Maternal folate deficiency has been associated with an increased risk for fetal neural tube defects. Concerns related to the effects of UV light on serum folate levels are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of psoriasis\", section on 'Folate deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Classic systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few oral treatments for psoriasis that have a good safety profile in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is a folate antagonist and FDA pregnancy category X (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). It should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used for treatment of psoriasis in a pregnant or lactating woman because it is teratogenic and may interfere with cellular metabolism in a nursing infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/18\">",
"     18",
"    </a>",
"    ]. Conception should be avoided for three months after the last dose because the drug can persist in the liver for several months. This drug is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acitretin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    is FDA pregnancy category X (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ), given (as discussed above) there is good evidence that retinoids significantly increase the incidence of severe congenital anomalies in experimental animals and humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/16\">",
"     16",
"    </a>",
"    ]. It should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used for treatment of psoriasis in a pregnant or lactating woman. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link&amp;anchor=H8#H8\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Teratogenicity and the iPLEDGE program'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    can be metabolized to etretinate in the body and etretinate has been identified in body fat as long as 52 months after stopping acitretin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/22\">",
"     22",
"    </a>",
"    ]. For this reason, experts recommend that pregnancy be avoided for three years after the last dose of acitretin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a calcineurin inhibitor and FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). It can be very effective in treating severe cutaneous psoriasis. Teratogenicity data in humans are derived primarily from organ transplant recipients. The risk of teratogenicity among the offspring of women treated with cyclosporine appears to be low, but premature labor and infants who are small for gestational age have been reported. Such findings may be related to the underlying medical condition rather than to the drug, and could also be related to both the medical condition and the drug. Another concern is that, in some studies, newborns whose mother consumed cyclosporine had a decrease in T and B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/12\">",
"     12",
"    </a>",
"    ]; however, it is not clear that this change had any clinical significance. The use of cyclosporine in pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    is FDA pregnancy category B (early",
"    <span class=\"nowrap\">",
"     pregnancy)/D",
"    </span>",
"    (late pregnancy) (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). Case series have found no increase in the incidence of adverse pregnancy outcomes with sulfasalazine exposure during pregnancy. Since sulfasalazine binds albumin, there is a theoretic risk that sulfasalazine will displace bilirubin from albumin and thereby increase the risk of kernicterus; however, there is no evidence that clinically significant displacement of bilirubin occurs. Although the safety profile of sulfasalazine is reassuring, it is minimally effective for treatment of psoriasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Sulfasalazine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing body of literature demonstrating that some of the biologic agents may be used safely during pregnancy. All three of the tumor necrosis factor (TNF)-inhibiting biologic therapies for psoriasis (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) are classified by the FDA as category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). However, data are limited. These drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'TNF inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     Ustekinumab",
"    </a>",
"    , a monoclonal antibody that targets IL-12 and IL-23, is also classified by the FDA as category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). Data on the safety of ustekinumab in pregnancy are primarily limited to animal studies. Individual cases of uncomplicated delivery of a healthy infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/23\">",
"     23",
"    </a>",
"    ] and spontaneous abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41030/abstract/24\">",
"     24",
"    </a>",
"    ] have been reported in patients treated with ustekinumab during pregnancy.",
"   </p>",
"   <p>",
"    The manufacturers of all the biologic medications for psoriasis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psoriatic arthritis manage ongoing registries of drug-exposed pregnant women and encourage enrollment of all such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of maternal psoriasis on pregnancy outcomes remains uncertain. Choosing drug therapies that pose the least risk to the fetus is the major issue in managing the pregnancies of affected women. Women should plan pregnancy when they are in remission, and ideally when they are off medication or are taking the minimum effective dose of medications that have the best fetal safety profiles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pregnancy counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psoriasis improves during pregnancy in 40 to 60 percent of women, worsens in 10 to 20 percent, and remains stable in the remainder; however, the disease flares in 50 percent of women postpartum. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pregnancy counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of therapy for pregnant women with psoriasis is based upon the severity of the disease and its impact on the patient's overall sense of well-being. Comorbidities, response to therapy, cost, and convenience are also important factors. We suggest a stepwise approach to management of mild to moderate psoriasis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with mild symptoms, we suggest topical rather than systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preference is topical corticosteroids because they are effective and there is more information supporting the safety of these agents in pregnancy than for calcipotriene or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44724?source=see_link\">",
"       coal tar",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"       Tazarotene",
"      </a>",
"      should be avoided, given it is a retinoid and retinoids are known teratogens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Topical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with moderate to severe symptoms, we suggest narrow band ultraviolet B phototherapy rather than oral therapies because of the safety and efficacy of phototherapy in pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with severe symptoms, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      rather than biologics, given insufficient data for use of biologics in pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We would consider administering biologics for severe, treatment-refractory psoriasis during pregnancy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/1\">",
"      Barker JN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/2\">",
"      Seeger JD, Lanza LL, West WA, et al. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology 2007; 214:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/3\">",
"      Yang YW, Chen CS, Chen YH, Lin HC. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol 2011; 64:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/4\">",
"      Cohen-Barak E, Nachum Z, Rozenman D, Ziv M. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2011; 25:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/5\">",
"      Dunna SF, Finlay AY. Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol 1989; 120:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/6\">",
"      Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005; 141:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/7\">",
"      Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996; 35:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/8\">",
"      Swanbeck G, Inerot A, Martinsson T, et al. Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol 1997; 137:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/9\">",
"      Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/10\">",
"      Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/11\">",
"      Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007; 334:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/12\">",
"      Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg 2002; 6:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/13\">",
"      Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996; 35:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/14\">",
"      Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin 2006; 24:167.",
"     </a>",
"    </li>",
"    <li>",
"     file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. (Accessed on December 19, 2007).",
"    </li>",
"    <li>",
"     www.reprotox.org (Accessed on December 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/17\">",
"      Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235:281.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 7th ed, Williams and Wilkins, Baltimore 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/19\">",
"      Franssen ME, van der Wilt GJ, de Jong PC, et al. A retrospective study of the teratogenicity of dermatological coal tar products. Acta Derm Venereol 1999; 79:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/20\">",
"      Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/21\">",
"      Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005; 53:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/22\">",
"      Maier H, H&ouml;nigsmann H. Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin. Lancet 1996; 348:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/23\">",
"      Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012; 11:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41030/abstract/24\">",
"      Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012; 6:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5663 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-AC56D16682-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41030=[""].join("\n");
var outline_f40_4_41030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREGNANCY COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TOPICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcipotriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coal tar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tazarotene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHOTOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Classic systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acitretin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14842?source=related_link\">",
"      Treatment selection for moderate to severe plaque psoriasis in special populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_4_41031="Ezetimibe and simvastatin: Drug information";
var content_f40_4_41031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ezetimibe and simvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/30/43493?source=see_link\">",
"    see \"Ezetimibe and simvastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/16/2311?source=see_link\">",
"    see \"Ezetimibe and simvastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vytorin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, 2-Azetidinone;",
"     </li>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: Dosing limitation: Simvastatin 80 mg is limited to patients that have been taking this dose for &gt;12 consecutive months without evidence of myopathy and are not currently taking or beginning to take a simvastatin dose-limiting or contraindicated interacting medication.",
"     </b>",
"     If patient is unable to achieve low-density lipoprotein-cholesterol (LDL-C) goal using the 40 mg dose of simvastatin, increasing to 80 mg dose is not recommended. Instead, switch patient to an alternative LDL-C-lowering treatment providing greater LDL-C reduction. After initiation or titration, monitor lipid response after &ge;2 weeks and adjust dose as necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia:",
"     </b>",
"     Oral: Ezetimibe 10 mg and simvastatin 40 mg once daily in the evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperlipidemias:",
"     </b>",
"     Oral: Initial: Ezetimibe 10 mg and simvastatin 10-20 mg once daily in the evening. Dosing range: Ezetimibe 10 mg and simvastatin 10-40 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients who require less aggressive reduction in LDL-C:",
"     </i>",
"     Initial: Ezetimibe 10 mg and simvastatin 10 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients who require &gt;55% reduction in LDL-C:",
"     </i>",
"     Initial: Ezetimibe 10 mg and simvastatin 40 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant medications:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Patients currently tolerating and requiring a dose of simvastatin 80 mg who require initiation of an interacting drug with a dose cap for simvastatin should be switched to an alternative statin with less potential for drug-drug interaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Amiodarone, amlodipine, or ranolazine:",
"     </i>",
"     Simvastatin dose should",
"     <b>",
"      not",
"     </b>",
"     exceed 20 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Diltiazem, dronedarone, or verapamil:",
"     </i>",
"     Simvastatin dose should",
"     <b>",
"      not",
"     </b>",
"     exceed 10 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in Chinese patients on niacin doses &ge;1 g/day:",
"     </b>",
"     Oral: Use caution with simvastatin doses exceeding 20 mg/day; because of an increased risk of myopathy, do not administer simvastatin 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     GFR &ge;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :  Ezetimibe 10 mg and simvastatin 20 mg once daily in the evening (higher doses should be used with caution).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F169632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate-to-severe impairment: Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/10: Ezetimibe 10 mg and simvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/20: Ezetimibe 10 mg and simvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/40: Ezetimibe 10 mg and simvastatin 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/80: Ezetimibe 10 mg and simvastatin 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9537090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Administer in the evening for maximal efficacy. Ezetimibe/simvastatin should be taken &ge;2 hours before or &ge;4 hours after administration of a bile acid sequestrant.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used in combination with dietary modification for the treatment of primary hypercholesterolemia and homozygous familial hypercholesterolemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vytorin&reg; may be confused with Vyvanse&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages refer to combination Vytorin&reg;. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (4%), pain in extremity (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ezetimibe, simvastatin, or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors including boceprevir and telaprevir, telithromycin), cyclosporine, danazol, and gemfibrozil",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart simvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with high doses (80 mg), concurrent use of other lipid-lowering medications (fibric acid derivatives, or niacin at doses &ge;1 g/day), other interacting drugs (eg, moderate-to-strong CYP3A4 inhibitors), age &ge;65 years, female gender, uncontrolled hypothyroidism, and renal dysfunction. Use with caution in patients taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use ezetimibe with caution in patients with mild hepatic impairment; not recommended for use with moderate or severe hepatic impairment. Use simvastatin with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated with active liver disease and with unexplained transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid use in patients with severe renal impairment (creatinine clearance not defined) unless patient has already tolerated simvastatin at a dose &ge;5 mg; use doses of simvastatin &gt;20 mg/day with caution and monitor closely for adverse events (eg, myopathy) in patients with moderate-to-severe renal impairment (ie, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). Initial dosage adjustment is not necessary in mild-to-moderate impairment. Renal impairment may also increase risk for myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use is contraindicated in patients taking strong CYP3A4 inhibitors, cyclosporine, danazol, and gemfibrozil (see Drug Interactions); if concurrent use of a contraindicated interacting medication is unavoidable, treatment with simvastatin should be suspended during use or consider the use of an alternative HMG-CoA reductase inhibitor void of CYP3A4 metabolism. Use caution and/or limit dose with amiodarone, amlodipine, diltiazem, ranolazine, verapamil, other fibrates, and lipid-lowering doses of niacin (&ge;1g/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chinese patients: Do not use high doses of simvastatin (80 mg) if concurrently taking niacin &ge;1 g/day; concomitant use may increase risk of myopathy in Chinese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;65 years of age; these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F169638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid excessive ethanol consumption (due to potential hepatic effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Simvastatin serum concentration may be increased when taken with grapefruit juice; avoid concurrent intake of large quantities (&gt;1 quart/day). Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice. Ezetimibe did not cause meaningful reductions in fat-soluble vitamin concentrations during a 2-week clinical trial. Effects of long-term therapy have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease simvastatin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F169620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F169621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg of rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F169618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vytorin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-10 mg (90): $568.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 mg (90): $568.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40 mg (90): $568.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-80 mg (90): $568.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize;  discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed after &ge;2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adacai (DO);",
"     </li>",
"     <li>",
"      Colmibe (EC);",
"     </li>",
"     <li>",
"      Duolip (CO);",
"     </li>",
"     <li>",
"      Inegy (AT, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IL, IT, NL, NO, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Maxetibe Plus (PY);",
"     </li>",
"     <li>",
"      Starstat-EZ (IN);",
"     </li>",
"     <li>",
"      Tiazomet-S (CO);",
"     </li>",
"     <li>",
"      Vasotenal EZ (PE);",
"     </li>",
"     <li>",
"      Vytorin (AR, AT, AU, BR, CL, CR, ES, GR, GT, HK, HN, ID, KP, MX, MY, NI, NZ, PA, PE, PH, SG, SV, TH, TW, UY, VE);",
"     </li>",
"     <li>",
"      Zintrepid (CN, MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ezetimibe: Inhibits absorption of cholesterol at the brush border of the small intestine, leading to a decreased delivery of cholesterol to the liver. Ezetimibe inhibits the enzyme Niemann-Pick C1-Like1 (NPC1L1), a sterol transporter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Simvastatin: A methylated derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Vytorin&reg; is equivalent to coadministered ezetimibe and simvastatin.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, \"2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-e118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peto R, Emberson J, Landray M, et al, &ldquo;Analysis of Cancer Data From Three Ezetimibe Trials,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1357-66. Available at  file://content.nejm.org/cgi/content/full/NEJMsa0806603",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/18765432/pubmed\" id=\"18765432\" target=\"_blank\">",
"        18765432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossebo AB, Pederson TR, Boman K, et al, &ldquo;Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1343-56.  Available at  file://content.nejm.org/cgi/content/full/NEJMoa0804602",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/18765433 /pubmed\" id=\"18765433 \" target=\"_blank\">",
"        18765433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, \"Intensive Lowering of LDL Cholesterol With 80 mg versus 20 mg Simvastatin Daily in 12,064 Survivors of Myocardial Infarction: A Double-Blind Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9753):1658-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/4/41031/abstract-text/21067805/pubmed\" id=\"21067805\" target=\"_blank\">",
"        21067805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8571 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-0ADC3428B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41031=[""].join("\n");
var outline_f40_4_41031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169644\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169629\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169630\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169631\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169632\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169612\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169601\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9537090\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169614\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169642\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169617\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169603\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169638\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169625\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169609\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169619\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169634\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169620\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169621\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169618\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169610\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539857\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169602\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169616\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/30/43493?source=related_link\">",
"      Ezetimibe and simvastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/16/2311?source=related_link\">",
"      Ezetimibe and simvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_4_41032="Pityriasis rosea drk skin 2";
var content_f40_4_41032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58283%7EDERM%2F87126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58283%7EDERM%2F87126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pityriasis rosea causes a papulosquamous eruption that frequently involves the thorax and assumes a characteristic \"Christmas tree\" appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and oval plaques are present on the trunk. A larger herald patch is on the right midback.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41032=[""].join("\n");
var outline_f40_4_41032=null;
var title_f40_4_41033="Carcinoma of the penis: Surgical and medical treatment";
var content_f40_4_41033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carcinoma of the penis: Surgical and medical treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41033/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41033/contributors\">",
"     Curtis A Pettaway, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41033/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/4/41033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/4/41033/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/4/41033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H118143968\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the penis are rare in the United States, Europe, and other industrialized countries. However, the incidence of penile carcinoma is much higher in parts of South America, Africa, and Asia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical and medical treatment of penile cancer is reviewed here. The epidemiology, clinical presentation, staging, and diagnosis of penile carcinoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42328?source=see_link\">",
"     \"Carcinoma of the penis: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14922442\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tumor Node Metastasis (TNM) staging system is used for staging carcinoma of the penis (",
"    <a class=\"graphic graphic_table graphicRef65885 \" href=\"mobipreview.htm?39/41/40605\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H282027136#H282027136\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Staging of penile cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following initial evaluation, staging and treatment of the primary lesion and of the regional nodes are performed separately. Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with an operable primary tumor, treatment depends on whether the lesion is associated with a low- or high-risk of recurrence. Men with a low-risk of recurrence are candidates for organ preserving treatment. In general, men with a high-risk of recurrence should be treated by penile amputation. (See",
"      <a class=\"local\" href=\"#H1159395689\">",
"       'Treatment of the primary tumor'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The need for surgical staging of the groin is based upon characteristics of the primary tumor (ie, grade, stage, lymphovascular invasion) and the presence or absence of palpable inguinal lymph nodes. (See",
"      <a class=\"local\" href=\"#H118145918\">",
"       'Approach to the regional nodes'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Men with locally advanced disease (ie, unresectable primary tumor or bulky lymphadenopathy) should be treated with primary medical therapy rather than initial surgery. (See",
"      <a class=\"local\" href=\"#H133644063\">",
"       'Approach to locally advanced or unresectable disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The approach to men who experience recurrent or metastatic disease is dependent on whether it is a localized recurrence or if metastatic disease is present. (See",
"      <a class=\"local\" href=\"#H133643934\">",
"       'Treatment of recurrent or metastatic disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159395689\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE PRIMARY TUMOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6182223\">",
"    <span class=\"h2\">",
"     Tumors with a low risk of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with Tis, Ta, or T1a penile tumors (",
"    <a class=\"graphic graphic_table graphicRef65885 \" href=\"mobipreview.htm?39/41/40605\">",
"     table 1",
"    </a>",
"    ) have a good prognosis following treatment and have a low risk of recurrence. These men are treated with limited excision (which is preferred) or other organ preserving strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159395874\">",
"    <span class=\"h3\">",
"     Limited excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objective of a limited excision is to preserve as much of the anatomy of the penis without compromising treatment goals in order to preserve penile length and sexual function. However, there are limited data on long-term outcomes to establish that it is equivalent to penile amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In one series of 39 men who underwent a glans-preserving procedure, one man (2.5 percent) required further surgery due to positive margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/2\">",
"     2",
"    </a>",
"    ]. At a median follow-up of 16 months, there was only one recurrence. (See",
"    <a class=\"local\" href=\"#H1159395886\">",
"     'Penile amputation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The options for a limited excision depend on the location of the tumor and extent of tumor involvement. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Circumcision, primarily for lesions involving the shaft skin",
"     </li>",
"     <li>",
"      Limited excisions of the glans or glans epithelium plus subepithelial connective tissue",
"     </li>",
"     <li>",
"      Removal of the glans (glansectomy) while leaving the penile shaft intact",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the risk of microscopic spread, excision to negative margins is critical, but a two centimeter margin (which was historically recommended) is no longer mandated. In one study of 64 penectomy specimens, grade was highly correlated with microscopic tumor extension beyond the grossly negative margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/4\">",
"     4",
"    </a>",
"    ]. The maximum tumor extension was 5 mm for grade 1 to 2 tumors and up to 10 mm for grade 3 tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6182384\">",
"    <span class=\"h3\">",
"     Additional organ preserving strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, alternative organ preserving strategies should be reserved for men with early stage penile cancer. Available options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatments primarily used for Tis lesion including topical therapy, laser ablation, and total glans resurfacing (TGS).",
"     </li>",
"     <li>",
"      Treatments used for Tis to T1 lesions, such as Mohs micrographic surgery.",
"     </li>",
"     <li>",
"      Treatments used for Tis to T1 lesions or for larger lesions in men who are not candidates for surgery, including penile radiation therapy (RT).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between them depends on the local expertise available and patient preference. These treatment modalities are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12814023\">",
"    <span class=\"h4\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both 5-fluourouracil (5-FU 5 percent cream every other day for four to six weeks) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream (5 percent cream applied five days a week for four to six weeks) are used to treat carcinoma in situ. However, reports on the long-term treatment outcomes with topical treatment are limited due to small sample sizes reported in single institution studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In one of the largest reports, 44 men received topical therapy for carcinoma in situ, with 5-FU used as first-line treatment and imiquimod as second-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/6\">",
"     6",
"    </a>",
"    ]. With a mean follow-up of 34 months, 31 men had a response to treatment and in 25 it was a complete response. With a median follow-up of 34 months (range, 12 to 180 months), 20 men remained in remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12814046\">",
"    <span class=\"h4\">",
"     Laser ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser ablation utilizes a laser energy source to penetrate the tumor bed. Commonly used energy sources include carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ), argon, Nd:YAG, and potassium titanyl phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/7\">",
"     7",
"    </a>",
"    ]. Laser ablation is associated with a high rate of resumption of sexual activity and sexual satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/8\">",
"     8",
"    </a>",
"    ], but appears most successful among patients with carcinoma in situ. For men considering laser ablation, the penis must be examined after application of five percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    to identify premalignant areas that will require treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Several retrospective series have provided information about the long-term outcome after laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The largest series, which evaluated 104 patients treated with excision plus laser therapy, reported a higher local recurrence rate compared to 100 men managed with partial amputation (38 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/12\">",
"     12",
"    </a>",
"    ]. However, local control was achieved in more than 90 percent of those who experienced a local recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12814061\">",
"    <span class=\"h4\">",
"     Total glans resurfacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total glans resurfacing involves the removal of the epithelial and subepithelial layers of the glans down to the corpus spongiosum, followed by placement of a skin graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence to support its use in low risk penile carcinoma is limited to single institution case reports and small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As an example, in one report, 25 men with carcinoma in situ were treated with either total or partial glans resurfacing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/15\">",
"     15",
"    </a>",
"    ]. With a mean follow-up of 29 months (range, 2 to 120 months), 24 men had excellent graft take. However, seven men (28 percent) required further surgery and in five of these cases, it was due to incidental detection of invasive disease. However the overall local recurrence rate was only 4 percent. Additional follow-up will be required to determine long-term disease control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12814071\">",
"    <span class=\"h4\">",
"     Mohs micrographic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMS involves layer-by-layer excision of the penile lesion. It is performed in multiple sessions and provides for improved precision while maximizing organ preservation. MMS is performed by a dermatologic surgeon with specific training, but requires careful coordination between the Mohs surgeon and the urologist to optimize patient care.",
"    <br/>",
"    <br/>",
"    The results with MMS are illustrated by a series of 33 patients (15 with invasive lesions) who underwent 41 MMS procedures between 1988 and 2006 at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/16\">",
"     16",
"    </a>",
"    ]. Overall, eight patients (32 percent) had a local recurrence, of which seven were managed with repeat MMS. Only one patient ultimately required penectomy and one patient died of metastatic penile cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12814079\">",
"    <span class=\"h4\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile RT can be administered by either external beam or interstitial brachytherapy techniques. However, the rate of tumor control, especially utilizing external beam radiotherapy, appears to be inferior to surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/17\">",
"     17",
"    </a>",
"    ]. This was shown in a 2009 review that included 67 men treated with RT with the following outcomes at a median follow-up of four years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer-specific survival at 10 years was 84 percent.",
"     </li>",
"     <li>",
"      The rate of penile preservation was 88 and 67 percent at five and ten years.",
"     </li>",
"     <li>",
"      Amputation was required for eight local recurrences and two men who experienced penile necrosis.",
"     </li>",
"     <li>",
"      Regional node recurrences were detected in 11 men. Only six underwent a node dissection; the other five had concomitant metastatic disease and were not surgical candidates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High doses of RT are generally needed to eradicate penile squamous cell carcinoma. Because of this, complications are common, including urethral mucositis, edema, and secondary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/18\">",
"     18",
"    </a>",
"    ]. Late complications (eg, telangiectasia, dyschromia, and superficial necrosis, urethral stricture, fistula formation, and meatal stenosis) can also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Prognostic factors for a poor response among patients treated with RT include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/17,23-25\">",
"     17,23-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total treatment dose less than 60 Gy or use of daily fractions less than 2 Gy",
"     </li>",
"     <li>",
"      Protracted treatment time greater than 45 days",
"     </li>",
"     <li>",
"      T3 or greater tumor",
"     </li>",
"     <li>",
"      Tumor larger than 4 cm",
"     </li>",
"     <li>",
"      High tumor grade",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Circumcision is necessary prior to RT to ensure full exposure of the penile cancer, allow resolution of any surface infection, and prevent maceration and preputial edema. For men who undergo RT, careful follow-up is still required given the risk of local recurrence. Such recurrences may be successfully treated with surgery if diagnosed early. (See",
"    <a class=\"local\" href=\"#H681108\">",
"     'Posttreatment surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6182816\">",
"    <span class=\"h2\">",
"     Tumors with a higher risk of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with T2 to T4 tumors (",
"    <a class=\"graphic graphic_table graphicRef65885 \" href=\"mobipreview.htm?39/41/40605\">",
"     table 1",
"    </a>",
"    ) or grade 3 tumors (of any T-stage) are considered to have a higher risk of recurrence. Although these patients are generally not candidates for a limited excision or organ preservation, there are some exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal, smaller T2-T3 tumors can be successfully treated with limited excisions as long as a tumor free margin can be achieved. (See",
"      <a class=\"local\" href=\"#H1159395874\">",
"       'Limited excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among select patients who refuse surgery, interstitial brachytherapy may be an option. (See",
"      <a class=\"local\" href=\"#H12814079\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men with penile cancer but no involvement of the penile glans or underlying corporal tissues (ie, stage T1, high grade tumors) may be candidates for excision of the penile shaft skin alone. (See",
"      <a class=\"local\" href=\"#H6182384\">",
"       'Additional organ preserving strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, patients with large, invasive (ie, bulky stage T2-T4) or destructive tumors (ie, bulky stage Ta, verrucous cancers) should be treated with penile amputation, in order to achieve rapid control of the primary tumor and to identify those patients requiring additional staging of the inguinal and regional nodes. (See",
"    <a class=\"local\" href=\"#H118145918\">",
"     'Approach to the regional nodes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159395886\">",
"    <span class=\"h3\">",
"     Penile amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile amputation includes either partial or total removal of the penis, which is determined by the location and the extent of the primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <strong>",
"       partial",
"      </strong>",
"      amputation involves the removal of the glans penis with or without a portion of the underlying corpora cavernosa. This procedure is usually performed for distal invasive tumors where resection of the tumor may leave the patient with sufficient penile length (to enable micturition while standing). In addition, preservation of penile length may be possible for select men with distal tumors amenable to removal of the glans alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1159395874\">",
"       'Limited excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A",
"      <strong>",
"       total",
"      </strong>",
"      amputation involves removal of the glans penis with the underlying corpus cavernosa. It is indicated if the tumor (using criteria described above) cannot be controlled without sparing sufficient length for the patient to stand and void. This is often the case for very large tumors extending down the shaft.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, partial penectomy is the more commonly performed procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In a recent review of seven surgical series, total penectomy accounted for only 271 procedures (20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/26\">",
"     26",
"    </a>",
"    ]. Recurrence rates following penectomy range from 3 to 33 percent with most series reporting recurrence rates of &le;10 percent. The most common complications of penectomy are meatal stenosis, which occurs in 4 to 9 percent of cases.",
"   </p>",
"   <p>",
"    Men who undergo amputation should be counselled regarding the option of penile reconstruction. Whether this is an option and the technical aspects of penile reconstruction is highly dependent on the type of surgery performed and the risk of recurrence following surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118145918\">",
"    <span class=\"h1\">",
"     APPROACH TO THE REGIONAL NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile cancer progresses in a very predictable manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/28\">",
"     28",
"    </a>",
"    ]. There is a prolonged locoregional phase followed by local spread manifest by involvement of the inguinal and pelvic nodes. Distant metastases develop following nodal metastases.",
"   </p>",
"   <p>",
"    For men with penile cancer, the presence and extent of inguinal node metastases is the most important prognostic factor for overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/27,29,30\">",
"     27,29,30",
"    </a>",
"    ]. There are multiple techniques used to evaluate the inguinal nodes, including ultrasound with fine needle aspiration (FNA) dynamic sentinel node biopsy (DSNB), and superficial inguinal lymph node dissection. The findings of a pathologically positive sentinel node or FNA identify patients who will require further surgery of the regional nodes. FNA and DSNB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H23781913#H23781913\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Staging techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542298563\">",
"    <span class=\"h2\">",
"     Clinically negative examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, men with a clinically negative inguinal node exam may need inguinal node staging based on the risk of tumor recurrence. Three factors can predict the risk of microscopic inguinal lymph node metastases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary tumor pathologic stage",
"      </strong>",
"      &mdash; Penile carcinoma in situ (Tis), verrucous carcinoma (Ta), and tumor that involves the subepithelial connective tissue alone (T1) have a risk of metastases from 4 to 14 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/28,31,32\">",
"       28,31,32",
"      </a>",
"      ]. In contrast, penile cancer with evidence of corporeal invasion (T2) is associated with approximately a 60 percent risk of inguinal node metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Tumor grade",
"      </strong>",
"      &mdash; Beyond tumor stage, metastatic potential is associated with high tumor grade. The reported risk of nodal invasion ranges between 0 and 48 percent for grade 1, 32 to 79 percent for grade 2, and 47 to 100 percent for grade 3 tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/34\">",
"       34",
"      </a>",
"      ]. In one study, men with moderate and high grade tumors had a significantly worse survival rate at ten years compared to those with well differentiated carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Presence or absence of lymphovascular invasion",
"      </strong>",
"      &mdash; The presence of lymphovascular invasion within the primary tumor is the strongest prognostic factor for lymph node metastases with an associated risk ranging from 60 to 80 percent risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these characteristics, recently convened penile cancer guidelines panels have stratified men into one of three risk groups that help determine the approach to the regional nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/28,35-37\">",
"     28,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H528989316\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with Tis, Ta, and T1 grade 1 tumors exhibiting no lymphovascular invasion and no palpable inguinal adenopathy are considered to be at low risk for nodal metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525425\">",
"    <span class=\"h3\">",
"     Intermediate or high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with T1 grade 2 or T2 grade 1 to 2 tumors with no evidence of lymphovascular invasion have intermediate risk disease. In contrast, men with grade 3 tumors, all tumors exhibiting lymphovascular invasion, and T2 or higher stage are considered to be at high risk for nodal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525452\">",
"    <span class=\"h3\">",
"     Inguinal staging procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both superficial inguinal lymph node dissection and sentinel lymph node mapping (referred to as dynamic sentinel node biopsy [DSNB]) are utilized to determine the presence of microscopic metastases among patients with invasive penile tumors and no palpable inguinal adenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H282027150#H282027150\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Regional node (N) assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with pathologic evidence of superficial inguinal node involvement, a therapeutic inguinal node dissection should be performed, which involves removal of those nodes deep to the fascia lata contained within the femoral triangle. A pelvic lymphadenectomy should also be performed because at least one study has shown that the superficial inguinal nodes drain into the upper lymph node quadrants lateral and medial to the femoral vessels, indicating that these nodes are at particular risk for involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/38\">",
"     38",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H461757611\">",
"     'Therapeutic inguinal node dissection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8904433\">",
"    <span class=\"h4\">",
"     Treatment of low-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of inguinal metastases among men with low-risk disease ranges from 0 to 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. Therefore, we agree with consensus recommendations from the European Association of Urology (EAU) and Society d&rsquo;Urologie Internationale (SIU) and offer these men surveillance rather than surgical staging, provided they are able to comply with follow-up recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H367006091#H367006091\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Clinically negative inguinal exam'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men who are unable or unwilling to proceed with surveillance should undergo inguinal node staging by DSNB or a superficial inguinal node dissection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H324012657#H324012657\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Dynamic sentinel node biopsy (DSNB)'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8904447\">",
"     'Treatment of intermediate or high-risk disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8904447\">",
"    <span class=\"h4\">",
"     Treatment of intermediate or high-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men at intermediate or high-risk should undergo either superficial inguinal node dissection or DSNB (provided the expertise and the facilities are available). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H367006091#H367006091\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Clinically negative inguinal exam'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further treatment of the regional nodes is guided by the pathologic findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with negative inguinal nodes following superficial inguinal node dissection or DSNB require no further therapy. We recommend posttreatment surveillance. (See",
"      <a class=\"local\" href=\"#H681108\">",
"       'Posttreatment surveillance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with one pathologically involved inguinal node (without extranodal extension) require a complete inguinal dissection. (See",
"      <a class=\"local\" href=\"#H461757611\">",
"       'Therapeutic inguinal node dissection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with two or more pathologically involved inguinal nodes or with evidence of extranodal extension should undergo a therapeutic inguinal node and pelvic node dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H461757611\">",
"       'Therapeutic inguinal node dissection'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H461757704\">",
"       'Pelvic node dissection'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9746503\">",
"    <span class=\"h2\">",
"     Clinically suspicious examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We stratify our approach to men who present with palpable regional adenopathy based on the clinical examination and the results of fine needle aspiration (FNA). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H23781946#H23781946\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Fine needle aspiration (FNA)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9746563\">",
"    <span class=\"h3\">",
"     Enlarged, unilateral inguinal node present",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who present with a unilateral and solitary inguinal node &lt;4 cm in size, we suggest a FNA of palpable inguinal nodes. If the FNA is positive, a complete (ie, superficial and deep) inguinal node dissection should be performed as it may provide therapeutic benefit in men found to have pathologically involved lymph nodes. All patients should also undergo a contralateral staging superficial inguinal node dissection as bilateral inguinal drainage from the primary tumor is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H461757611\">",
"     'Therapeutic inguinal node dissection'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8904447\">",
"     'Treatment of intermediate or high-risk disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based on the results at inguinal node dissection we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No further treatment for patients with up to a single positive inguinal lymph node and no evidence of extranodal extension of cancer. (See",
"      <a class=\"local\" href=\"#H681108\">",
"       'Posttreatment surveillance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A pelvic node dissection if two or more pathologically involved nodes are identified or extranodal extension is seen on final pathology. This information defines patients at higher risk for recurrence and for pelvic lymph node metastases. (See",
"      <a class=\"local\" href=\"#H461757704\">",
"       'Pelvic node dissection'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9746975\">",
"    <span class=\"h3\">",
"     Multiple or bilateral inguinal nodes present",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with evidence of multiple or bilateral palpable inguinal nodes, we suggest a FNA as the initial staging evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H23781946#H23781946\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Fine needle aspiration (FNA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the FNA is negative, we recommend a superficial inguinal dissection with intraoperative frozen sections to determine the pathologic stage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=see_link&amp;anchor=H20463851#H20463851\">",
"       \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Superficial inguinal lymph node dissection (SILND)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the FNA is positive, then the patient likely has stage N2 metastatic penile cancer and is at risk for treatment failure with surgery alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. We suggest neoadjuvant chemotherapy followed by surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/28\">",
"       28",
"      </a>",
"      ]. An alternative approach would consist of a therapeutic inguinal and pelvic node dissection, provided the patient is a surgical candidate. (See",
"      <a class=\"local\" href=\"#H133644063\">",
"       'Approach to locally advanced or unresectable disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461757845\">",
"    <span class=\"h3\">",
"     Surgical techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with proven inguinal metastases should undergo a therapeutic inguinal node dissection. This and the indications for a pelvic lymph node dissection are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461757611\">",
"    <span class=\"h4\">",
"     Therapeutic inguinal node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A therapeutic inguinal lymph node dissection is the most reliable means of establishing the presence or absence of nodal metastases and simultaneously treating any disease that is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. For men with microscopically involved nodes, long-term cure may be achieved in as many as 90 percent using this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In the largest series, 65 patients who were surgically treated for stage I to III penile cancer were followed for a minimum of five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/43\">",
"     43",
"    </a>",
"    ]. More patients who underwent surgical treatment of the primary lesion followed by inguinal lymphadenectomy remained disease free compared to those who underwent surgical treatment of the primary lesion alone for stage II (88 versus 38 percent) or stage III (66 versus 0 percent) disease.",
"   </p>",
"   <p>",
"    An inguinal node dissection can be performed as an open procedure or accomplished using a laparoscopic technique, if the expertise is available. Laparoscopic surgery offers the potential of removing all inguinal nodes while minimizing complications. However, there is little evidence that a laparoscopic approach is comparable to an open surgical approach at this time. Therefore, further experience with this technique is required before it should be offered as a standard option to men with penile cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461757704\">",
"    <span class=\"h4\">",
"     Pelvic node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of multiple pathologically identified inguinal nodes increases the risk for pelvic lymph node involvement. Therefore, in the presence of pathologically involved inguinal nodes, we proceed with a pelvic node dissection. While one series suggests that men with a single inguinal node involved without evidence of extracapsular extension rarely have pelvic node involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/47\">",
"     47",
"    </a>",
"    ], another series reported that the risk of pelvic node involvement ranges from 22 percent if one to three nodes are positive to 57 percent if more than three inguinal nodes are involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/48\">",
"     48",
"    </a>",
"    ]. However, whether pelvic node dissection influences survival outcomes is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133644063\">",
"    <span class=\"h1\">",
"     APPROACH TO LOCALLY ADVANCED OR UNRESECTABLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who present with an unresectable primary tumor, bulky inguinal adenopathy, or bilateral inguinal node involvement are not candidates for surgical treatment at the time of diagnosis. For these men, we suggest neoadjuvant chemotherapy. The objective of neoadjuvant chemotherapy is to induce a treatment response that will allow for subsequent surgical therapy. However, there is no preferred regimen to treat men with locally advanced or unresectable disease. In general, regimens used in the metastatic setting may be used. (See",
"    <a class=\"local\" href=\"#H118145232\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For men who are candidates for neoadjuvant chemotherapy, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    administered over three hours on day 1),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 3), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 3) at three to four week intervals for four cycles. This recommendation is based on a phase II study involving 30 men with advanced penile cancer who were treated with this regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/49\">",
"     49",
"    </a>",
"    ]. An objective response was observed in 15 (50 percent), and nine patients remained disease-free at 34 months. Variables significantly associated with improvement in overall and recurrence free survival included both an objective response to chemotherapy and the presence of only unilateral and minimal residual disease at the time of surgery.",
"   </p>",
"   <p>",
"    All men who have a clinical response to treatment and those with stable disease should undergo surgical resection. Those who do not respond to neoadjuvant chemotherapy should be offered palliative therapy. The approach to men in this situation is similar to that of men with metastatic disease. (See",
"    <a class=\"local\" href=\"#H118145232\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22657471\">",
"    <span class=\"h1\">",
"     IS THERE A ROLE FOR ADJUVANT TREATMENT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to inform the role of adjuvant therapy in men with penile carcinoma. However, given the suggested benefit of neoadjuvant chemotherapy for men with locally advanced or unresectable disease and the overall poor prognosis for men with high-risk features, adjuvant chemotherapy is a reasonable option for men with high risk features who were not treated in the neoadjuvant setting, if any of the following pathologic findings are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic lymph node metastases",
"     </li>",
"     <li>",
"      Extranodal extension",
"     </li>",
"     <li>",
"      Bilateral inguinal node involvement",
"     </li>",
"     <li>",
"      Greater than three positive nodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in the neoadjuvant setting, we suggest the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . However, there are other cisplatin based alternative regimens that have been utilized in the metastatic setting that also exhibit activity. (See",
"    <a class=\"local\" href=\"#H133644063\">",
"     'Approach to locally advanced or unresectable disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H118145232\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adjuvant RT to the inguinal regions may be useful in penile cancer but has not been rigorously evaluated. It was found to be efficacious (in terms of both local control and survival outcomes) in a randomized trial that involved women with pathologically node-positive vulvar cancer (a disease site with similar lymphatic drainage as penile cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, to the extent that metastatic inguinal nodes due to penile cancer behave in a similar fashion as those due to vulvar cancer, adjuvant RT to the inguinal regions might be beneficial among pN2-N3 disease. However, pelvic RT was not associated with a reduction in the risk of pelvic relapse in vulvar cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/51\">",
"     51",
"    </a>",
"    ]. Therefore, adjuvant pelvic RT remains investigational and should not be used outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H681108\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, most invasive penile carcinomas were treated with radical surgery and the frequency of local recurrences was low. With the increasing utilization of penile-sparing therapies, more cases of local recurrence may be seen. Many of those with a locoregional relapse may be treated with curative intent using aggressive, locoregional therapy. (See",
"    <a class=\"local\" href=\"#H6624224\">",
"     'Localized recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All men treated for penile carcinoma require close follow-up. Although there are no high quality data looking at outcomes to inform an optimal follow-up paradigm, posttreatment surveillance guidelines have been published by the EAU and the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. While both are suitable, our posttreatment surveillance mirrors NCCN recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who underwent an",
"      <strong>",
"       organ-sparing procedure",
"      </strong>",
"      (eg, partial penectomy, Mohs, laser), physical examination should be carried out every three months for the first two years, every six months during year 3 to 5, then yearly up to ten years.",
"     </li>",
"     <li>",
"      For patients who underwent a",
"      <strong>",
"       partial or total penectomy",
"      </strong>",
"      , physical examination should be performed every six months for the first two years, every 12 months during years 3 to 5.",
"     </li>",
"     <li>",
"      For patients who did not undergo inguinal lymphadenectomy (ie, opted for",
"      <strong>",
"       surveillance",
"      </strong>",
"      ), physical examination should be carried out every two to three months for the first two years, every four months during year three, then every six months in years 4 and 5.",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       pN0",
"      </strong>",
"      disease following a lymph node dissection, physical examination should be performed every four months for the first two years, every six months during year 3, and then yearly during years 4 and 5.",
"     </li>",
"     <li>",
"      Patients who underwent a lymph node dissection with pathologically positive nodes",
"      <strong>",
"       (pN+)",
"      </strong>",
"      are at high-risk for local",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distant recurrence. These patients should undergo follow-up with physical examination every three months for the first two years, every four months during year 3, then every six months in years 4 and 5. We would recommend an abdominal and pelvic CT scan during all visits during the first two years for node positive patients. Imaging studies are optional after this period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133643934\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with a history of penile cancer are at risk for both a localized recurrence and distant metastases. The approach to treatment is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6624224\">",
"    <span class=\"h2\">",
"     Localized recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following treatment, men are at risk for a penile (if not treated with penile amputation) or an inguinal recurrence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men who have a penile recurrence, we proceed with a penile amputation in most cases. However, whether a partial or total amputation is required depends on the location and extent of the tumor recurrence. Occasionally, carefully selected patients (ie, those with small and low grade recurrences) may be treated with a second organ preserving strategy. Overall, disease specific survival is good when local recurrence is promptly recognized and appropriately treated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For men who experience an inguinal recurrence, the prognosis is poor. We suggest multimodality treatment using either chemotherapy plus surgery or chemoradiation (with or without surgery) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any patient undergoing resection of a recurrent penile tumor should also undergo nodal re-evaluation. A prophylactic bilateral inguinal lymph node dissection (especially in the setting of an invasive recurrent tumor where a prior node dissection was not performed), in spite of its morbidity, is a reasonable treatment option in cases of recurrent disease. Although the data are limited to small case series, this seems to confer the best chance at long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/43,53,54\">",
"     43,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For men with fixed groin nodes or high local tumor burden not amenable to surgical resection, treatment is palliative. Radiation can alleviate pressure associated with tumor compression and improve the quality of life of men with incurable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/55\">",
"     55",
"    </a>",
"    ]. Otherwise, for men who wish to receive further treatment and are deemed good candidates for systemic treatment, we suggest palliative chemotherapy. (See",
"    <a class=\"local\" href=\"#H118145232\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118145232\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with or who develop disseminated disease (M1), we individualize treatment based on the patient&rsquo;s performance status and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/56\">",
"     56",
"    </a>",
"    ]. For men with a good performance status (eg, Karnofsky performance status &gt;80) (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ), we suggest a trial of chemotherapy. For all others, we prefer best supportive care.",
"   </p>",
"   <p>",
"    Chemotherapy results in overall response rates of up to 30 percent in patients with metastatic penile carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/49,57,58\">",
"     49,57,58",
"    </a>",
"    ]. A 2010 review of the literature concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing regimens were most active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/59\">",
"     59",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    had a similar level of activity, it was associated with a high incidence of clinically significant pulmonary toxicity and should not be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active combination regimens in penile carcinoma have been identified, but there are no clinical trials to inform a preferred regimen. A choice should be based on patient and provider preference after an individualized consideration of their potential toxicities. Active regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H133644063\">",
"       'Approach to locally advanced or unresectable disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 1) plus 5-fluourouracil (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      IV on days 1 to 5) every three to four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15) given on a 28-day cycle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is only low quality evidence available, single agents that appear to have activity in advanced or metastatic penile carcinoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      every three weeks) &mdash; In a trial of 25 patients, the overall response rate was 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/61\">",
"       61",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (30 to 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week) &mdash; The response rate ranges from 40 to 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potentially active agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and the epidermal growth factor receptor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , although the experience with these agents is limited to their administration as part of a combination regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/4/41033/abstract/58,63-65\">",
"     58,63-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H760194087\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9747377\">",
"    <span class=\"h2\">",
"     Approach to the primary tumor",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men with Tis, Ta, or T1 penile tumors (",
"      <a class=\"graphic graphic_table graphicRef65885 \" href=\"mobipreview.htm?39/41/40605\">",
"       table 1",
"      </a>",
"      ) have a good prognosis with treatment and are at a low risk of recurrence. Therefore, we recommend a limited excision rather than penile amputation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who refuse or are not surgical candidates, we offer an organ-sparing approach. Options include topical therapy, partial excision of the glans penis (Mohs surgery), resection of the glans penis skin and subepithelial connective tissue (ie, glans resurfacing), laser ablation, and radiation therapy. (See",
"      <a class=\"local\" href=\"#H6182223\">",
"       'Tumors with a low risk of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men with bulky stage T2 to T4 tumors (",
"      <a class=\"graphic graphic_table graphicRef65885 \" href=\"mobipreview.htm?39/41/40605\">",
"       table 1",
"      </a>",
"      ) are considered to have a higher risk of recurrence with organ preserving strategies. For these men, we suggest penile amputation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1159395886\">",
"       'Penile amputation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9747385\">",
"    <span class=\"h2\">",
"     Approach to the regional nodes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with a clinically negative inguinal examination, we stratify our approach to the regional nodes based on their risk of nodal involvement (see",
"      <a class=\"local\" href=\"#H542298563\">",
"       'Clinically negative examination'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with Tis, Ta, or T1 grade 1 tumor (low grade), we suggest surveillance provided they are able to comply with posttreatment surveillance (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For men who are unable or unwilling to proceed with surveillance, we suggest an inguinal node evaluation using dynamic sentinel node biopsy (DSNB), provided the expertise is available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If DSNB cannot be performed, we proceed with a superficial inguinal dissection. (See",
"      <a class=\"local\" href=\"#H8904433\">",
"       'Treatment of low-risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We perform a bilateral superficial inguinal node dissection or dynamic sentinel node biopsy for men with T2 or higher tumors and all grade 3 tumors (intermediate and high grade). For men with up to one pathologically involved lymph node without extranodal extension, we suggest a therapeutic inguinal node dissection rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For men with two or more pathologically involved nodes or men with extranodal extension identified, we suggest therapeutic inguinal node plus pelvic node dissections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H525425\">",
"       'Intermediate or high risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surveillance for men who had a negative staging biopsy or superficial inguinal node dissection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with an ipsilateral clinically suspicious examination of the groin (see",
"      <a class=\"local\" href=\"#H9746503\">",
"       'Clinically suspicious examination'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a fine needle aspiration (FNA). If the FNA is positive, we suggest an ipsilateral therapeutic inguinal node dissection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If the FNA is negative, we proceed with an ipsilateral superficial inguinal dissection with intraoperative frozen sections for further evaluation.",
"     </li>",
"     <li>",
"      All men should also undergo a contralateral superficial inguinal node dissection.",
"     </li>",
"     <li>",
"      For men with pathologically involved nodes detected, we suggest a pelvic node dissection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9746563\">",
"       'Enlarged, unilateral inguinal node present'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with multiple or bilateral palpable inguinal nodes, we suggest an FNA. If the FNA is negative, we proceed with a unilateral or bilateral (as appropriate) superficial dissection with intraoperative frozen sections for further evaluation. If the FNA is positive, we suggest neoadjuvant chemotherapy followed by surgery rather than further surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative strategy includes surgical resection followed by adjuvant therapy. (See",
"      <a class=\"local\" href=\"#H133644063\">",
"       'Approach to locally advanced or unresectable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with unresectable penile carcinoma or bulky adenopathy, we suggest neoadjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who are candidates for neoadjuvant chemotherapy, we suggest a three-drug combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;Definitive surgery should be performed in men who have an objective response to treatment. (See",
"      <a class=\"local\" href=\"#H133644063\">",
"       'Approach to locally advanced or unresectable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adjuvant chemotherapy for men with high-risk factors for relapse (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest a combination regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      for four cycles (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22657471\">",
"       'Is there a role for adjuvant treatment?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men who are not candidates for adjuvant chemotherapy, we suggest adjuvant radiation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9747567\">",
"    <span class=\"h2\">",
"     Treatment of recurrent or metastatic disease",
"    </span>",
"   </p>",
"   <p>",
"    (see",
"    <a class=\"local\" href=\"#H133643934\">",
"     'Treatment of recurrent or metastatic disease'",
"    </a>",
"    above)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men who experience a local recurrence, we suggest a total penile amputation be performed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition based on the grade and stage of the local recurrence the inguinal region should be re-evaluated and treated as appropriate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6624224\">",
"       'Localized recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with or who develop disseminated disease (M1), we individualize treatment based on the patient&rsquo;s performance status and symptoms. For men with a good performance status (eg, Karnofsky performance status &gt;80) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ), we suggest a trial of chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For all others, we prefer best supportive care. (See",
"      <a class=\"local\" href=\"#H118145232\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620049711\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Donald F Lynch, who contributed to previous versions of this topic review card.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/1\">",
"      Minhas S, Kayes O, Hegarty P, et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005; 96:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/2\">",
"      Pietrzak P, Corbishley C, Watkin N. Organ-sparing surgery for invasive penile cancer: early follow-up data. BJU Int 2004; 94:1253.",
"     </a>",
"    </li>",
"    <li>",
"     Brown G, Khadra A, Abdelraheem A, et al. Predictors of penile cancer recurrence following conservative surgical resection (abstract 995). Eur Urol Suppl 2009; 8:369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/4\">",
"      Agrawal A, Pai D, Ananthakrishnan N, et al. The histological extent of the local spread of carcinoma of the penis and its therapeutic implications. BJU Int 2000; 85:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/5\">",
"      Minhas S, Manseck A, Watya S, Hegarty PK. Penile cancer--prevention and premalignant conditions. Urology 2010; 76:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/6\">",
"      Alnajjar HM, Lam W, Bolgeri M, et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 2012; 62:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/7\">",
"      Pettaway CA, Davis JW. Contemporary Management of Penile Carcinoma. Part I: Overview of Epidemiology, Diagnosis, Staging and Management of the Primary Tumor. AUA Update Series 2012; 15:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/8\">",
"      Windahl T, Skeppner E, Andersson SO, Fugl-Meyer KS. Sexual function and satisfaction in men after laser treatment for penile carcinoma. J Urol 2004; 172:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/9\">",
"      Tietjen DN, Malek RS. Laser therapy of squamous cell dysplasia and carcinoma of the penis. Urology 1998; 52:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/10\">",
"      Frimberger D, Hungerhuber E, Zaak D, et al. Penile carcinoma. Is Nd:YAG laser therapy radical enough? J Urol 2002; 168:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/11\">",
"      Windahl T, Andersson SO. Combined laser treatment for penile carcinoma: results after long-term followup. J Urol 2003; 169:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/12\">",
"      Lont AP, Gallee MP, Meinhardt W, et al. Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol 2006; 176:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/13\">",
"      Meijer RP, Boon TA, van Venrooij GE, Wijburg CJ. Long-term follow-up after laser therapy for penile carcinoma. Urology 2007; 69:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/14\">",
"      Hadway P, Corbishley CM, Watkin NA. Total glans resurfacing for premalignant lesions of the penis: initial outcome data. BJU Int 2006; 98:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/15\">",
"      Shabbir M, Muneer A, Kalsi J, et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol 2011; 59:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/16\">",
"      Shindel AW, Mann MW, Lev RY, et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol 2007; 178:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/17\">",
"      Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol 2009; 27:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/18\">",
"      Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol 1997; 32:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/19\">",
"      Delannes M, Malavaud B, Douchez J, et al. Iridium-192 interstitial therapy for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 1992; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/20\">",
"      Gerbaulet A, Lambin P. Radiation therapy of cancer of the penis. Indications, advantages, and pitfalls. Urol Clin North Am 1992; 19:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/21\">",
"      Kelley CD, Arthur K, Rogoff E, Grabstald H. Radiation therapy of penile cancer. Urology 1974; 4:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/22\">",
"      Kaushal V, Sharma SC. Carcinoma of the penis. A 12-year review. Acta Oncol 1987; 26:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/23\">",
"      Gotsadze D, Matveev B, Zak B, Mamaladze V. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol 2000; 38:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/24\">",
"      Sarin R, Norman AR, Steel GG, Horwich A. Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. Int J Radiat Oncol Biol Phys 1997; 38:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/25\">",
"      Soria JC, Fizazi K, Piron D, et al. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol 1997; 8:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/26\">",
"      Solsona E, Bahl A, Brandes SB, et al. New developments in the treatment of localized penile cancer. Urology 2010; 76:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/27\">",
"      Ornellas AA, Kinchin EW, N&oacute;brega BL, et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol 2008; 97:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/28\">",
"      Pettaway CA, Pagilaro L. Penile squamous carcinoma. Part II: Contemporary management of the inguinal region. AUA Update Series 2012; 31:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/29\">",
"      Marconnet L, Rigaud J, Bouchot O. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol 2010; 183:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/30\">",
"      Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006; 93:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/31\">",
"      Solsona E, Iborra I, Ric&oacute;s JV, et al. Corpus cavernosum invasion and tumor grade in the prediction of lymph node condition in penile carcinoma. Eur Urol 1992; 22:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/32\">",
"      Hall MC, Sanders JS, Vuitch F, et al. Deoxyribonucleic acid flow cytometry and traditional pathologic variables in invasive penile carcinoma: assessment of prognostic significance. Urology 1998; 52:111.",
"     </a>",
"    </li>",
"    <li>",
"     Pettaway CA, Lynch D, and Davis J. Tumors of the penis. In: Urology, 9, AJ Wein, LR Kavoussi, AC Novick, et al..  (Eds), WB Saunders, Philadelphia 2007. p.959.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/34\">",
"      Ficarra V, Akduman B, Bouchot O, et al. Prognostic factors in penile cancer. Urology 2010; 76:S66.",
"     </a>",
"    </li>",
"    <li>",
"     Solsona E, Algaba F, Horenblas S, et al. European Association of Urology guidelines on penile cancer. file://www.uroweb.org/fileadmin/user_upload/Guidelines/10%20Penile%20Cancer.pdf (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/36\">",
"      Solsona E, Algaba F, Horenblas S, et al. EAU Guidelines on Penile Cancer. Eur Urol 2004; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/37\">",
"      Heyns CF, Fleshner N, Sangar V, et al. Management of the lymph nodes in penile cancer. Urology 2010; 76:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/38\">",
"      Spiess PE, Izawa JI, Bassett R, et al. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 2007; 177:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/39\">",
"      Leijte JA, Hughes B, Graafland NM, et al. Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis. J Clin Oncol 2009; 27:3325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/40\">",
"      Lont AP, Kroon BK, Gallee MP, et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007; 177:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/41\">",
"      McDougal WS. Carcinoma of the penis: improved survival by early regional lymphadenectomy based on the histological grade and depth of invasion of the primary lesion. J Urol 1995; 154:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/42\">",
"      Heyns CF, van Vollenhoven P, Steenkamp JW, et al. Carcinoma of the penis--appraisal of a modified tumour-staging system. Br J Urol 1997; 80:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/43\">",
"      McDougal WS, Kirchner FK Jr, Edwards RH, Killion LT. Treatment of carcinoma of the penis: the case for primary lymphadenectomy. J Urol 1986; 136:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/44\">",
"      Kroon BK, Horenblas S, Lont AP, et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005; 173:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/45\">",
"      Coblentz TR, Theodorescu D. Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penis. J Urol 2002; 168:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/46\">",
"      Sotelo R, Sanchez-Salas R, Clavijo R. Endoscopic inguinal lymph node dissection for penile carcinoma: the developing of a novel technique. World J Urol 2009; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/47\">",
"      Horenblas S, van Tinteren H, Delemarre JF, et al. Squamous cell carcinoma of the penis. III. Treatment of regional lymph nodes. J Urol 1993; 149:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/48\">",
"      Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol 1993; 72:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/49\">",
"      Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28:3851.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Guidelines Version 1.2012: Penile Cancer. file://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/51\">",
"      Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009; 114:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/52\">",
"      Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/53\">",
"      Johnson DE, Lo RK. Management of regional lymph nodes in penile carcinoma. Five-year results following therapeutic groin dissections. Urology 1984; 24:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/54\">",
"      Fraley EE, Zhang G, Manivel C, Niehans GA. The role of ilioinguinal lymphadenectomy and significance of histological differentiation in treatment of carcinoma of the penis. J Urol 1989; 142:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/55\">",
"      Gonz&aacute;lez Domingo M, Gonz&aacute;lez San Segundo C. Penile cancer: are there currently indications for radiotherapy?. Arch Esp Urol 2011; 64:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/56\">",
"      Connell CF, Berger NA. Management of advanced squamous cell carcinoma of the penis. Urol Clin North Am 1994; 21:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/57\">",
"      Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999; 161:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/58\">",
"      Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/59\">",
"      Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010; 76:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/60\">",
"      Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/61\">",
"      Di Lorenzo G, Federico P, Buonerba C, et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011; 60:1280.",
"     </a>",
"    </li>",
"    <li>",
"     Pizzocaro G, Tan WW, Dreicer R. Chemotherapy for penile cancer. In: Comprehensive Textbook of Genitourinary Oncology, 3, Vogelzang NJ, Scardino PT, Shipley WU, et al.  (Eds), Lippincott Williams and WIlkins, Philadelphia 2006. p.827.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/63\">",
"      Power DG, Galvin DJ, Cuffe S, et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009; 27:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/64\">",
"      Necchi A, Nicolai N, Colecchia M, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011; 29:e650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/4/41033/abstract/65\">",
"      Joerger M, Warzinek T, Klaeser B, et al. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004; 63:778.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16866 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41033=[""].join("\n");
var outline_f40_4_41033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H760194087\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118143968\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14922442\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159395689\">",
"      TREATMENT OF THE PRIMARY TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6182223\">",
"      Tumors with a low risk of recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159395874\">",
"      - Limited excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6182384\">",
"      - Additional organ preserving strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12814023\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12814046\">",
"      Laser ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12814061\">",
"      Total glans resurfacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12814071\">",
"      Mohs micrographic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12814079\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6182816\">",
"      Tumors with a higher risk of recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159395886\">",
"      - Penile amputation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118145918\">",
"      APPROACH TO THE REGIONAL NODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542298563\">",
"      Clinically negative examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H528989316\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525425\">",
"      - Intermediate or high risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525452\">",
"      - Inguinal staging procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8904433\">",
"      Treatment of low-risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8904447\">",
"      Treatment of intermediate or high-risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9746503\">",
"      Clinically suspicious examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9746563\">",
"      - Enlarged, unilateral inguinal node present",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9746975\">",
"      - Multiple or bilateral inguinal nodes present",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H461757845\">",
"      - Surgical techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H461757611\">",
"      Therapeutic inguinal node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H461757704\">",
"      Pelvic node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133644063\">",
"      APPROACH TO LOCALLY ADVANCED OR UNRESECTABLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22657471\">",
"      IS THERE A ROLE FOR ADJUVANT TREATMENT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H681108\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133643934\">",
"      TREATMENT OF RECURRENT OR METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6624224\">",
"      Localized recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H118145232\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H760194087\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9747377\">",
"      Approach to the primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9747385\">",
"      Approach to the regional nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9747567\">",
"      Treatment of recurrent or metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H620049711\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16866|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/41/40605\" title=\"table 1\">",
"      TNM staging penile cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42328?source=related_link\">",
"      Carcinoma of the penis: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26840?source=related_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_4_41034="Trichorrhexis nodosa";
var content_f40_4_41034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87473%7EDERM%2F87475%7EDERM%2F87478%7EDERM%2F87480%7EDERM%2F87483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87473%7EDERM%2F87475%7EDERM%2F87478%7EDERM%2F87480%7EDERM%2F87483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Trichorrhexis nodosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Broom-like fraying of the hair shaft is seen in trichorrhexis nodosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Trichoschisis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse fractures are evident in several hair shafts in this hair specimen from a patient with trichothiodystrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Pili torti",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This flattened, twisted hair shaft was taken from a patient with Menkes disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Monilethrix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Elliptical nodes are visible in these hair shafts from a patient with monilethrix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Trichorrhexis invaginata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trichorrhexis invaginata is a ball and socket-like deformity of the hair shaft that is seen in patients with Netherton syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41034=[""].join("\n");
var outline_f40_4_41034=null;
var title_f40_4_41035="Differential diagnosis of leptomeningeal metastases";
var content_f40_4_41035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of leptomeningeal metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skull base metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dural metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parenchymal brain metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary leptomeningeal melanomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opportunistic (tuberculosis, cryptococcus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis (bacterial or viral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        West Nile virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Langerhans cell histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bell's palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Artifact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-radiotherapy nerve root thickening and/or enhancement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enhancing meningeal blood vessels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41035=[""].join("\n");
var outline_f40_4_41035=null;
var title_f40_4_41036="Pleural fluid in SLE";
var content_f40_4_41036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pleural disease in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        SLE",
"       </td>",
"       <td class=\"subtitle1\">",
"        HF",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Malignancy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Symptoms",
"       </td>",
"       <td>",
"        Pleurisy",
"       </td>",
"       <td>",
"        Dyspnea",
"       </td>",
"       <td>",
"        Pleurisy",
"       </td>",
"       <td>",
"        Varied",
"       </td>",
"       <td>",
"        Pleurisy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Fluid characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clarity",
"       </td>",
"       <td>",
"        Clear",
"       </td>",
"       <td>",
"        Clear",
"       </td>",
"       <td>",
"        Cloudy",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Normal &gt; Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red cells",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White cells",
"       </td>",
"       <td>",
"        3 - 5000",
"       </td>",
"       <td>",
"        &lt;10,000",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complement",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immune complexes",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANA",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LDH",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        RF",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41036=[""].join("\n");
var outline_f40_4_41036=null;
var title_f40_4_41037="Clopidogrel outcome in CURE";
var content_f40_4_41037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Clopidogrel improves outcome in an acute coronary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the CURE trial, 12,562 patients with an acute coronary syndrome were randomly assigned to clopidogrel or placebo in combination with aspirin. After a one year follow-up the incidence of the first primary outcome (cardiovascular death, nonfatal myocardial infarction, or stroke) was significantly lower with clopidogrel (9.3 versus 11.4 percent for placebo). This benefit was largely due to fewer nonfatal infarctions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Yusuf S, Zhao F, Mehta HR, et al. N Engl J Med 2001; 345:494",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41037=[""].join("\n");
var outline_f40_4_41037=null;
var title_f40_4_41038="Guttate morphea";
var content_f40_4_41038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Guttate morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Guttate morphea is characterized by multiple, small (2 to 10 mm in diameter), hypopigmented and pigmented papules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41038=[""].join("\n");
var outline_f40_4_41038=null;
var title_f40_4_41039="Advanced asbestosis CXR";
var content_f40_4_41039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced asbestosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note characteristic features: fibrotic bands superimposed on a background of widespread irregular opacities, shaggy heart border and septal thickening, extensive pleural changes, and blunted costophrenic angles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med 2004; 170:692; www.atsjournals.org",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_4_41039=[""].join("\n");
var outline_f40_4_41039=null;
